Lexaria Bioscience (LEXX) Change in Accured Expenses (2014 - 2026)

Lexaria Bioscience has disclosed Change in Accured Expenses across 13 years of filings, most recently posting -$1.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.2 million, down 181.55% year-over-year; the trailing twelve-month figure through Feb 2026 was -$1.6 million (down 192.68% YoY), and the FY2025 annual result was $396637.0, down 52.01% from the prior year.
• Change in Accured Expenses came in at -$1.2 million for Q1 2026 at Lexaria Bioscience, down from -$37613.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.5 million in Q1 2025 to a low of -$1.2 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is -$37613.0 (2025), against an average of -$407.82.
• Across the five-year window, Change in Accured Expenses tumbled 13829.01% in 2023 and surged 3591.7% in 2025, its largest moves.
• Lexaria Bioscience's Change in Accured Expenses stood at $90442.0 in 2022, then tumbled by 255.87% to -$140973.0 in 2023, then slumped by 465.66% to -$797423.0 in 2024, then surged by 95.28% to -$37613.0 in 2025, then sank by 3204.24% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$37613.0 (Q4 2025), and $4787.0 (Q3 2025), per Business Quant data.